OGD Mock Study on Acetriptan
This article was originally published in The Gold Sheet
The example builds on the Conformia ACE case study by treating that product as the reference product for the development of a generic product, said OGD Chemist Robert Lionberger. The hypothetical example used a dummy drug molecule known as "Acetriptan," which is classified under the biopharmaceutics classification system as a Class II compound displaying poor aqueous solubility (less than 0.015 mg/mL) across the physiological pH range.
You may also be interested in...
First to file, worst to file? FDA looks to turn the tables on the generics submissions race and award first-to-file status to ANDA applicants who invest in quality by design. Agency urges generics firms to adopt QbD approach by 2011. The problem is many non-QbD first-to-file ANDAs languish in review while firms learn how to make the products, wasting industry and FDA resources - especially with complex modified-release products. Once in production, recalls and warning letters could follow while firms continue learning the hard way.
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.